In their review on the safety of long-acting b2-agonists in asthma, Rodrigo et al 1 report that severe asthma-related complications were more frequent in patients receiving formoterol 24 mg twice daily (0.9%) than in those receiving formoterol 12 mg twice daily (0.4%) or placebo (0.2%) in a multicentre randomised trial. 2 The original study reports different percentages of asthma-related complications in the treatment groups (table 1), and both serious asthma exacerbations and a combined outcome including serious asthma exacerbations, asthmarelated discontinuations and emergency visits for asthma did not show statistically significant differences between the treatment groups.

